Mizuho Markets Americas LLC Increases Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Mizuho Markets Americas LLC boosted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 17.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,379,582 shares of the biopharmaceutical company’s stock after purchasing an additional 204,475 shares during the quarter. Mizuho Markets Americas LLC owned approximately 1.05% of Dynavax Technologies worth $15,369,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in DVAX. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Dynavax Technologies by 1.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC boosted its holdings in shares of Dynavax Technologies by 2.4% in the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 1,303 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,679 shares during the period. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the period. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Dynavax Technologies by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 1,900 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Down 8.8 %

Shares of NASDAQ:DVAX opened at $12.21 on Friday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 93.93 and a beta of 1.34. The company has a 50 day moving average of $11.37 and a two-hundred day moving average of $11.30.

Analyst Ratings Changes

DVAX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group dropped their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.